The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
about
DNA adducts in humans as biomarkers of exposure to environmental and occupational carcinogensUse of Accelerator Mass Spectrometry in Human Health and Molecular ToxicologyAdverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study.Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cellsHuman DNA adduct measurements: state of the artDNA adducts as exposure biomarkers and indicators of cancer riskCisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitroMolecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research.Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance.Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumoursDo genetic polymorphisms modulate response rate and toxicity of Cisplatin associated with radiotherapy in laryngeal squamous cell carcinoma?: a case reportNucleotide excision repair and anti-cancer chemotherapyPlatinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapyPharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.Oxaliplatin-DNA adduct formation in white blood cells of cancer patientsMechanism of double-base lesion bypass catalyzed by a Y-family DNA polymerase.Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Immunocytochemical analysis of cisplatin-induced platinum-DNA adducts with double-fluorescence video microscopyDevelopment of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts.DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Fluorometric imaging methods for palladium and platinum and the use of palladium for imaging biomolecules.A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.Quantitative analysis of Gd@C82(OH)22 and cisplatin uptake in single cells by inductively coupled plasma mass spectrometry.Cisplatin-induced alterations in the functional spermatogonial stem cell pool and niche in C57/BL/6J mice following a clinically relevant multi-cycle exposure.Human exposure monitoring, dosimetry, and cancer risk assessment: the use of antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA.Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.Rapid polymerase chain reaction assay to detect variation in the extent of gene-specific damage between cisplatin- or VP-16-resistant and sensitive lung cancer cell lines.Correlation of gene-specific damage with cisplatin between human adenocarcinoma cells and peripheral blood mononuclear cells analyzed by polymerase chain reaction-stop assay.
P2860
Q23920037-ADDDED6C-B9C9-45EC-9AED-7EF8624D9D07Q28818313-F5D8A8EB-4B9D-4319-9950-E5DB96F8B7E9Q33601281-FC5127AE-3D3E-4921-BDB7-C4164355CF7AQ34328748-1DADB4D3-BE34-4F13-AFCA-8C468B7AC2BEQ34637114-A45A7669-5474-4432-B1A4-296763A6E4A8Q34638964-ECC2005E-C998-4BD3-B1D6-860C59F4A2FFQ34843715-463A5884-95B8-4256-895C-047DAD33C6F1Q34844361-886893A6-0186-4B61-8AE5-48AF259443DFQ35031455-BBA9748F-52F6-4289-8626-45A150BE8A21Q35131936-5DEBA46E-9D64-4B0C-B3EA-A080DF7834ACQ35978496-69404FB1-7A92-4B3E-8763-1CD07168AE71Q36074388-9A2376E0-C200-4E44-BCF4-0041E5B0A78EQ36080482-7B1E67D4-9085-4E50-A980-F3BBEAD9B424Q36135407-661E790D-395D-4C56-A127-BFD5CDD774C4Q36152077-6A4B5CF4-93A5-4C7D-8549-5A1227DDB35FQ36254803-FFA5862C-8E6B-4854-A069-96630210D773Q36431475-7B8298A4-ACE8-4E88-B211-11FDFE3E9D2DQ36617271-FC1D275D-95F0-4FAA-B725-C829F0704A5BQ36740632-243D9AC0-7937-4DCB-8C16-58EC6DF55A7FQ36777842-30D4298A-D4B0-4FBC-8458-5DE606AB5F1DQ36817080-BADA87E9-E0E6-43C2-8FB4-924864F9084AQ36875580-49873954-5511-4586-B557-9427BED73732Q37309473-90AD6A5F-B93A-4ECB-974D-6BF1E40B2FA9Q37736567-0D23E545-3198-4601-829C-A49A26E16E7AQ38364149-CBF546AC-4C18-4649-A11F-2AA0E4FEC2F9Q38706298-813996BF-F5CD-4D4A-987F-81B123E8E96FQ38907617-7A864D50-65E0-46BF-85EE-64D708BCE8B0Q39007526-08F9A07F-9490-45E7-A9B6-9B5694343F7CQ40700919-D651B2BF-3001-4A91-A4A6-31287F863A7DQ42144353-CF41490A-31FF-43E5-8429-94FB6E1FE754Q55128662-42AB5F4F-4EEF-480E-839E-FF39730B3481Q55209541-565C7A5B-3D6E-4AFF-A65B-CE6D6E0C3D19
P2860
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
@en
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
@nl
type
label
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
@en
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
@nl
prefLabel
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
@en
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
@nl
P2093
P356
P1433
P1476
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
@en
P2093
P304
P356
10.1093/CARCIN/9.10.1909
P407
P577
1988-10-01T00:00:00Z